EA200300629A1 - Конденсированные производные пурина как антагонисты рецепторов аденозина a - Google Patents

Конденсированные производные пурина как антагонисты рецепторов аденозина a

Info

Publication number
EA200300629A1
EA200300629A1 EA200300629A EA200300629A EA200300629A1 EA 200300629 A1 EA200300629 A1 EA 200300629A1 EA 200300629 A EA200300629 A EA 200300629A EA 200300629 A EA200300629 A EA 200300629A EA 200300629 A1 EA200300629 A1 EA 200300629A1
Authority
EA
Eurasian Patent Office
Prior art keywords
adenosine
antagonists
purin
receptors
condensed derivatives
Prior art date
Application number
EA200300629A
Other languages
English (en)
Other versions
EA009814B1 (ru
Inventor
Ко-Чунг Лин
Чи Ву
Original Assignee
Байоджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен, Инк. filed Critical Байоджен, Инк.
Publication of EA200300629A1 publication Critical patent/EA200300629A1/ru
Publication of EA009814B1 publication Critical patent/EA009814B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Соединения формулы I и II раскрыты как антагонисты рецепторов аденозина подтипа A. Эти соединения можно использовать для лечения различных заболеваний и нарушений, включая системную гипертонию, почечную недостаточность, диабет, астму, отечное состояние, застойную сердечную недостаточность и почечную дисфункцию.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200300629A 2000-12-01 2001-11-30 Конденсированные производные пурина как антагонисты рецепторов аденозина а EA009814B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25065800P 2000-12-01 2000-12-01
PCT/US2001/044991 WO2002044182A1 (en) 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
EA200300629A1 true EA200300629A1 (ru) 2003-12-25
EA009814B1 EA009814B1 (ru) 2008-04-28

Family

ID=22948640

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300629A EA009814B1 (ru) 2000-12-01 2001-11-30 Конденсированные производные пурина как антагонисты рецепторов аденозина а

Country Status (33)

Country Link
US (2) US6605601B2 (ru)
EP (1) EP1347981B1 (ru)
JP (2) JP2004514723A (ru)
KR (1) KR20040011439A (ru)
CN (1) CN100497340C (ru)
AR (1) AR035400A1 (ru)
AT (1) ATE394402T1 (ru)
AU (2) AU1997702A (ru)
BG (1) BG107849A (ru)
BR (1) BR0115833A (ru)
CA (1) CA2430508C (ru)
CZ (1) CZ20031513A3 (ru)
DE (1) DE60133931D1 (ru)
EA (1) EA009814B1 (ru)
EE (1) EE200300260A (ru)
ES (1) ES2305139T3 (ru)
GE (1) GEP20094697B (ru)
HK (1) HK1059927A1 (ru)
HU (1) HUP0400530A3 (ru)
IL (1) IL156046A0 (ru)
IS (1) IS6821A (ru)
MX (1) MXPA03004857A (ru)
MY (1) MY127120A (ru)
NO (1) NO20032483L (ru)
NZ (1) NZ526511A (ru)
PL (1) PL362642A1 (ru)
SK (1) SK6552003A3 (ru)
TR (1) TR200300766T2 (ru)
TW (1) TWI293301B (ru)
UA (1) UA75625C2 (ru)
WO (1) WO2002044182A1 (ru)
YU (1) YU42903A (ru)
ZA (2) ZA200304067B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005430B2 (en) * 1999-12-24 2006-02-28 Kyowa Hakko Kogyo Co., Ltd. Fused purine derivatives
CZ20031513A3 (cs) * 2000-12-01 2003-09-17 Biogen, Inc. Kondenzované purinové deriváty jako antagonisty A1 adenosinového receptoru
CA2516250A1 (en) * 2003-02-19 2004-09-02 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
MXPA05011371A (es) 2003-04-25 2005-12-01 Novacardia Inc Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
CN1777608A (zh) * 2003-04-25 2006-05-24 协和发酵工业株式会社 稠合嘧啶衍生物
WO2005009343A2 (en) * 2003-06-06 2005-02-03 Endacea, Inc. A1 adenosine receptor antogonists
US20080161327A1 (en) * 2005-03-11 2008-07-03 Aderis Pharmaceuticals, Inc. Substituted 9-Alkyladenines and the Use Thereof
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
JP2009532479A (ja) * 2006-04-06 2009-09-10 ノヴァカーディア，インク． アデノシンａ１受容体アンタゴニストと抗痙攣薬の同時投与
DK2018380T3 (da) 2006-05-19 2012-01-23 Abbott Lab CNS-aktiverede kondenserede bi-heterocyklisk-substituerede azabicykliske alkanderivater
EP2035009A1 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
AR061625A1 (es) 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a
DE602007010312D1 (de) 2006-06-23 2010-12-16 Incyte Corp Purinonderivate als hm74a-agonisten
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
WO2011063268A2 (en) * 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
CN111770926B (zh) * 2018-01-04 2023-07-21 因佩蒂斯生物科学有限公司 三环化合物、组合物及其医药应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
ES2152207T3 (es) * 1989-10-20 2001-02-01 Kyowa Hakko Kogyo Kk Derivados condensados de la purina.
ATE349424T1 (de) 1991-09-23 2007-01-15 Univ Florida State Beta-lactame verwendbar zur herstellung von substituierten isoserinestern mit metallalkoxiden
EP0884318A4 (en) * 1996-10-07 2002-10-23 Kyowa Hakko Kogyo Kk CONDENSED PURINE DERIVATIVES
EP1014995A4 (en) * 1997-06-18 2005-02-16 Aderis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSES CONSECUTIVE TO REVASCULARIZATION INTERVENTIONS
US6489331B1 (en) * 1998-07-02 2002-12-03 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
US7005430B2 (en) * 1999-12-24 2006-02-28 Kyowa Hakko Kogyo Co., Ltd. Fused purine derivatives
CZ20031513A3 (cs) * 2000-12-01 2003-09-17 Biogen, Inc. Kondenzované purinové deriváty jako antagonisty A1 adenosinového receptoru

Also Published As

Publication number Publication date
MXPA03004857A (es) 2003-08-19
ES2305139T3 (es) 2008-11-01
EE200300260A (et) 2003-08-15
CA2430508C (en) 2010-05-18
NO20032483D0 (no) 2003-06-02
IS6821A (is) 2003-05-20
YU42903A (sh) 2006-05-25
ATE394402T1 (de) 2008-05-15
BR0115833A (pt) 2003-10-28
NO20032483L (no) 2003-07-30
NZ526511A (en) 2005-04-29
MY127120A (en) 2006-11-30
SK6552003A3 (en) 2003-12-02
GEP20094697B (en) 2009-06-10
JP2004514723A (ja) 2004-05-20
BG107849A (bg) 2004-01-30
ZA200304067B (en) 2005-05-30
EA009814B1 (ru) 2008-04-28
CZ20031513A3 (cs) 2003-09-17
US20030220358A1 (en) 2003-11-27
US20020111333A1 (en) 2002-08-15
HUP0400530A2 (hu) 2004-06-28
US7022686B2 (en) 2006-04-04
UA75625C2 (en) 2006-05-15
HUP0400530A3 (en) 2007-05-29
JP2010053148A (ja) 2010-03-11
AR035400A1 (es) 2004-05-26
DE60133931D1 (de) 2008-06-19
US6605601B2 (en) 2003-08-12
AU2002219977B2 (en) 2008-01-24
AU1997702A (en) 2002-06-11
KR20040011439A (ko) 2004-02-05
TR200300766T2 (tr) 2004-09-21
PL362642A1 (en) 2004-11-02
CA2430508A1 (en) 2002-06-06
WO2002044182A1 (en) 2002-06-06
TWI293301B (en) 2008-02-11
HK1059927A1 (en) 2004-07-23
CN1481387A (zh) 2004-03-10
EP1347981B1 (en) 2008-05-07
ZA200408755B (en) 2005-07-27
IL156046A0 (en) 2003-12-23
CN100497340C (zh) 2009-06-10
EP1347981A1 (en) 2003-10-01

Similar Documents

Publication Publication Date Title
EA200300629A1 (ru) Конденсированные производные пурина как антагонисты рецепторов аденозина a
EA200300118A1 (ru) Тетрагидропиридино- или пиперидиногетероциклические производные
EA200600925A1 (ru) Производные триазола в качестве антагонистов вазопрессина
EA200100757A1 (ru) Хинолинкарбоксамиды в качестве противовирусных агентов
EA200300593A1 (ru) Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора
EA200500017A1 (ru) Новые соединения
EA200200770A1 (ru) Производные пурина
ATE470662T1 (de) Piperazinylpyrazinverbindungen als agonisten oder antagonisten am serotonin-5ht-2-rezeptor
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
DK1131315T3 (da) Polyhydroxylerede heterocykliske derivater som antikoagulanter
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
EA200400893A1 (ru) N-арил-2-оксазолидинон-5-карбоксамиды, их производные и их применение в качестве антибактериальных средств
EA200201119A1 (ru) Лиганды меланокортиновых рецепторов
EA200300919A1 (ru) N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
DK1385515T3 (da) Spiropyrazole forbindelser
HN2003000285A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
EA200300527A1 (ru) Новые способы лечения синдрома "усталых ног"
SE9702773D0 (sv) Novel compounds
BR0007864A (pt) Composto, e, uso de um composto
ATE316531T1 (de) Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
EA200200732A1 (ru) Замещенные производные фенилпиперазина, их получение и применение
EA200500830A1 (ru) Производные имидазохинолина в качестве лигандов аденозиновых a3 рецепторов
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
EA200301317A1 (ru) Производные аминохинолина и его применение в качестве лигандов аденозина a3
EA200100517A1 (ru) Антагонисты 5ht1 для антидепрессантной терапии

Legal Events

Date Code Title Description
HC1A Change in name of an applicant in a eurasian application
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU